The consensus of the experts was that all patients with advanced-stage non-squamous NSCLC should be tested for EGFR mutations and ALK rearrangements/fusions, PD-L1 protein expression with IHC, and alterations associated with BRAF, ERBB2, KRAS, MET, NRG1, NTRK1, NTRK2, NTRK3, RET, and ROS1. The gene discussed is ALK; the disease is non-small cell lung carcinoma.